A b s t r a c t
Bone mineral density is influenced by environmental factors, such as dietary calcium intake and physical activity, and by genetic determinants. Since vitamin D is important in calcium metabolism and bone turnover, it has been suggested that polymorphisms for the vitamin D receptor (VDR) gene may be one of these factors. In a large population of healthy whites, Morrison and coworkers 1 -2 described an association between the VDR-BB genotype and higher levels of osteocalcin, an index of bone turnover. They also found that postmenopausal women with the BB genotype had low bone mineral density in the lumbar spine and femoral neck, resulting in a lower fracture threshold. They suggested that the presence of the B allele of the VDR gene influenced the bone turnover and, therefore, could be considered a genetic marker of osteoporosis. Although the specific molecular role was not described fully, they suggested that the B allele might be associated with increased transcriptional activity of the VDR gene and prolonged messenger RNA (mRNA) stability. These results were not confirmed fully in further studies, 3^ probably because of differences in sample size and ethnic background of the populations.
Vitamin D works at different sites, including the intestine, kidney, bone, and parathyroid glands 78 ; in these sites, calcitriol interacts with the nuclear VDR, causing inhibition of the parathyroid hormone gene transcription and up-regulation of the VDR itself. In renal failure, the long-term phosphorus retention and the reduced vitamin D production induce secondary hyperparathyroidism, which includes elevated serum parathyroid hormone (PTH) levels, calcium-phosphorus balance alterations, and high bone turnover osteodystrophy, the so-called osteitis fibrosa (OF). 9 However, an increasing number of patients undergoing dialysis have been seen with low levels of circulating PTH (hypoparathyroidism) and abnormalities of bone remodeling, leading to low turnover osteodystrophy, named aplastic bone disease (ABD We studied whether VDR polymorphism influenced the parathyroid endocrine status of patients with end-stage renal disease.
Materials and Methods

Patients
From a large multicentric white population (northwest Italy) of patients undergoing dialysis, we selected 99 with end-stage renal disease (89 patients receiving hemodialysis and 10 patients receiving continuous ambulatory peritoneal dialysis); all had abnormal parathyroid function and biochemical findings of pathologic bone metabolism. None of the patients were diabetic. To control phosphatemia, all were receiving oral calcium carbonate or calcium acetate or magnesium carbonate as phosphate binders. Patients with hyperparathyroidism were treated with calcitriol, orally or intravenously. To avoid hypercalcemia, we reduced the calcium concentration in the dialysate as needed (from 1.75 to 1.5 and finally to 1.25 mmol/L for patients undergoing hemodialysis if necessary).
The study group comprised 60 men and 39 women. The characteristics of the group, given as mean ± SD, were as follows: age, 56.5 ± 13.2 years; dialytic age, 69.8 ± 66. 
Methods
After DNA extraction from peripheral leukocytes by a standard method with phenol-chloroform, the polymorphisms of the VDR gene were analyzed by amplification with the polymerase chain reaction (Eppendorf Mastercycler 5330, Eppendorf, Hamburg, Germany) of an 800-base-pair DNA fragment, between exons 8 and 9 of the gene. The polymerase chain reaction was done using the following temperature scheme for 30 cycles: 95°C for 1 minute, 52°C for 2 minutes, and 72°C for 3 minutes. 13 The amplified fragments were digested with Bsml restriction enzyme (Roche, Italy) and fractionated by electrophoresis in a 1.5% agarose gel, detecting 3 genotypes: Bb, bb, BB, where b means the presence of the restriction site and B the absence of the site. Serum PTH was measured by a 2-site immunoradiometric assay (Allegro IRMA PTH kit, Nichols Institute, San Juan, Capistrano, CA); serum calcium, phosphorus, and ALP levels were measured by standard automated techniques.
Statistical Analysis
We used logistic regression analysis and 1-way analysis of variance followed by the Student / test (Statistical Package for the Social Sciences for MS WINDOWS, release 6.1, SPSS, Chicago, IL) for comparison of the biochemical data, which are expressed as mean ± SD. Differences between groups for the frequencies of genotypes and alleles were examined by using the % 2 test (SPSS for MS WINDOWS release 6.1).
Results
In our study population, the genotype frequencies were under genetic (or Hardy-Weinberg) equilibrium: 53 patients had the Bb genotype (54%), 26 patients had the BB (26%), and 20 patients had the bb (20%). In the group with hypoparathyroidism, the B allele was overrepresented (60% vs 44%, P < .05), and the BB genotype was more frequent (71% vs 37%, P < .05); similar results were found for the b allele and bb genotype in the hyperparathyroidism group (56% vs 40%, P < .05; 63% vs 29%, P < .05). When the % 2 test was used to compare the frequencies of the 3 genotypes, including the heterozygous condition, there was only a trend toward statistical significance (P = .07) ITable 21.
Comparison of the clinical and biochemical variables in the hypoparathyroidism and hyperparathyroidism groups showed a significant difference for the dialytic age, for serum ALP levels, and, obviously, for PTH levels (P < .001). These data suggest that patients with lower PTH levels tend to have a lower dialytic age and a low turnover bone disease, as confirmed by lower levels of serum ALP.
We also considered whether the 3 VDR genotypes might account for differences in clinical and biochemical data. This analysis I Figure II revealed 8 (14) 24 (56) 7 (16) 12(28) * Data are given as number (percentage). Hypoparathyroidism vs hyperparathyroidism, P = .07; x 2 test.
BB and Bb genotype were older than those with the bb genotype (59.6 and 60.1 vs 52.9 years), even though this difference was not significant. In our population, the prevalence of hypoparathyroidism was higher among patients with the BB genotype than those with the bb genotype (73% vs 40%, P = .05) or Bb genotype (73% vs 54.7%, P = .57).
Discussion
We studied patients with altered parathyroid gland function secondary to renal failure. Several factors influence the parathyroid status in the uremic patient. Extreme parathyroid dysfunction in a patient undergoing dialysis does not arise suddenly, and its appearance seems to be related to the duration of renal failure and dialytic age. The hyperparathyroidism was, in fact, related to a longer time on dialysis. The etiopathogenic mechanism is not fully understood and is probably multifactorial. Increased PTH levels are a consequence of an initial transient hyperphosphatemic and hypocalcemic status concomitant with pathologic PTH degradation and lower absolute or relative serum calcitriol levels. The origin of hypoparathyroidism might be linked to hypercalcemia or hypophosphatemia, aluminum intoxication, or inappropriate vitamin D treatment. It also has been demonstrated that calcitriol can influence parathyroid cell function and differentiation, accounting for one of the possible factors involved in the parathyroid dysfunction. 9 In consideration of these factors, our interest was focused on whether the polymorphisms of the VDR gene influence the development of hypoparathyroidism or hyperparathyroidism in end-stage renal disease.
The relationship between the VDR genotype and parathyroid function is controversial. Carling et al 14 not confirm this correlation. The 99 patients undergoing dialysis who were included in the present study were divided into 2 groups according to their PTH levels. Those with hypoparathyroidism had lower ALP activity, which means less bone turnover. This inadequate bone turnover, also defined by the low PTH and ALP levels, usually is associated with ABD. The patients with hyperparathyroidism, instead, had higher bone turnover and a late-onset endocrine alteration. The higher ALP levels, which trigger accelerated bone turnover, and the increased PTH levels are established characteristics of OF. Although we did not have bone biopsy specimens for all patients, it has been demonstrated that hypoparathyroidism correlates with the histologic pattern of ABD and hyperparathyroidism with OF. 11 The hypoparathyroidism group had a significantly higher prevalence of the B allele and the hyperparathyroidism group of the b allele (P < .05). The BB genotype was more represented in the hypoparathyroidism group than in the hyperparathyroidism group, but there was only a trend toward statistical significance (33.9% vs 16.3, % 2 test; P = .07). These results seem to agree with the notion that the B allele is related to greater mRNA activity and stability.
When we compared the clinical and biochemical variables for the different genotypes independently of the PTH status, patients with the B allele and the BB genotype, compared with those with the b allele and bb genotype, had a lower dialytic age and lower serum PTH and ALP levels. Therefore, a patient with end-stage renal disease with the BB genotype has a greater likelihood of developing hypoparathyroidism and the related ABD. As regards the lower dialytic age in the hypoparathyroidism group, since time influences parathyroid function, these results might have been influenced by the wide range of dialytic ages in the study group.
The B allele and BB genotype seem somewhat more frequent in patients with hypoparathyroidism, although the statistical significance is documented only for the allele frequency. This finding might help identify a genetic risk of hypoparathyroidism associated with diminished bone turnover, in accordance with the hypothesis proposed by Morrison etal. 
